{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:17:50Z","timestamp":1768004270487,"version":"3.49.0"},"reference-count":26,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b17-00118","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T22:17:09Z","timestamp":1506809829000},"page":"1654-1660","source":"Crossref","is-referenced-by-count":6,"title":["Inhibitory Effects of Gastrointestinal Drugs on CYP Activities in Human Liver Microsomes"],"prefix":"10.1248","volume":"40","author":[{"given":"Mariko","family":"Iwase","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimitsu","family":"Kurata","sequence":"additional","affiliation":[{"name":"Faculty of Arts and Sciences at Fujiyoshida, Showa University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hokuto","family":"Namba","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kiuchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) The World Health Organization. \u201cThe Role of the Pharmacist in Self-Care and Self-Medication.\u201d: \u2039http:\/\/apps.who.int\/medicinedocs\/pdf\/whozip32e\/whozip32e.pdf\u203a, cited 5 January, 2017."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hayashi M, Masuda S, Kimura H. Key information providers, channels, and characteristics of Japanese consumers\u2019 informed choices of over-the-counter medications. <i>Springerplus<\/i>, <b>4<\/b>, 737 (2015).","DOI":"10.1186\/s40064-015-1549-7"},{"key":"3","unstructured":"3) Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. <i>In vitro<\/i> characterization of cytochrome P450 2D6 inhibition by classic histamine H<sub>1<\/sub> receptor antagonists. <i>Drug Metab. Dispos.<\/i>, <b>26<\/b>, 536\u2013539 (1998)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hamelin BA, Bouayad A, M\u00e9thot J, Jobin J, Desgagn\u00e9s P, Poirier P, Allaire J, Dumesnil J, Turgeon J. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. <i>Clin. Pharmacol. Ther.<\/i>, <b>67<\/b>, 466\u2013477 (2000).","DOI":"10.1067\/mcp.2000.106464"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Marechal JD, Yu J, Brown S, Kapelioukh I, Rankin EM, Wolf CR, Roberts GC, Paine MJ, Sutcliffe MJ. <i>In silico<\/i> and <i>in vitro<\/i> screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. <i>Drug Metab. Dispos.<\/i>, <b>34<\/b>, 534\u2013538 (2006).","DOI":"10.1124\/dmd.105.007625"},{"key":"6","unstructured":"6) Haaz MC, Rivory L, Rich\u00e9 C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. <i>Cancer Res.<\/i>, <b>58<\/b>, 468\u2013472 (1998)."},{"key":"7","unstructured":"7) Haaz MC, Rich\u00e9 C, Rivory LP, Robert J. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes. <i>Drug Metab. Dispos.<\/i>, <b>26<\/b>, 769\u2013774 (1998)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Miura Y, Chishima S, Takeyama S. Studies of metabolic pathways of trimebutine by simultaneous administration of trimebutine and its deuterium-labeled metabolite. <i>Drug Metab. Dispos.<\/i>, <b>17<\/b>, 455\u2013462 (1989).","DOI":"10.1016\/S0090-9556(25)07655-X"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sakurai E, Iwase M, Kurata N, Nagai T, Hirashima H, Nishimura Y, Yasuhara H. The inhibitory effet of amoxapine on cytochrome P450 enzyme activity in human liver microsomes. <i>Showa Univ. J. Med. Sci.<\/i>, <b>16<\/b>, 329\u2013338 (2004).","DOI":"10.15369\/sujms1989.16.329"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. <i>J. Pharmacol. Sci.<\/i>, <b>96<\/b>, 293\u2013300 (2004).","DOI":"10.1254\/jphs.FP0040296"},{"key":"11","unstructured":"11) The Ministry of Health, Labor and Welfare of Japan. \u201cDrug interaction guideline for drug development and labeling recommendations\u201d (draft for public comment) (2014).: \u2039http:\/\/www.solvobiotech.com\/documents\/Japanese_DDI_guideline_(draft)_2014Jan.pdf\u203a, cited 5 January, 2017."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM. Evaluation of various static <i>in vitro<\/i>\u2013<i>in vivo<\/i> extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug. <i>Clin. Pharmacol. Ther.<\/i>, <b>95<\/b>, 189\u2013198 (2014).","DOI":"10.1038\/clpt.2013.187"},{"key":"13","unstructured":"13) Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. <i>Clin. Pharmacol. Ther.<\/i>, <b>81<\/b>, 298\u2013304 (2007)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 \u201cpie.\u201d <i>Drug Metab. Dispos.<\/i>, <b>34<\/b>, 880\u2013886 (2006).","DOI":"10.1124\/dmd.105.008672"},{"key":"15","unstructured":"15) Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. Drug\u2013drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios. <i>Drug Metab. Dispos.<\/i>, <b>32<\/b>, 1201\u20131208 (2004)."},{"key":"16","unstructured":"16) Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 <i>in vitro<\/i> probe substrates. <i>Br. J. Clin. Pharmacol.<\/i>, <b>48<\/b>, 716\u2013727 (1999)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. <i>J. Biol. Chem.<\/i>, <b>261<\/b>, 5051\u20135060 (1986).","DOI":"10.1016\/S0021-9258(19)89213-X"},{"key":"18","unstructured":"18) von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. Triazolam biotransformation by human liver microsomes <i>in vitro<\/i>: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>276<\/b>, 370\u2013379 (1996)."},{"key":"19","unstructured":"19) Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP. <i>In vitro<\/i> metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. <i>Drug Metab. Dispos.<\/i>, <b>25<\/b>, 1191\u20131199 (1997)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kantola T, Kivist\u00f6 KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. <i>Clin. Pharmacol. Ther.<\/i>, <b>64<\/b>, 177\u2013182 (1998).","DOI":"10.1016\/S0009-9236(98)90151-5"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Neuvonen PJ, Kantola T, Kivist\u00f6 KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. <i>Clin. Pharmacol. Ther.<\/i>, <b>63<\/b>, 332\u2013341 (1998).","DOI":"10.1016\/S0009-9236(98)90165-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. <i>Drug Metab. Dispos.<\/i>, <b>36<\/b>, 986\u2013990 (2008).","DOI":"10.1124\/dmd.107.020099"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>60<\/b>, 575\u2013581 (2004).","DOI":"10.1007\/s00228-004-0815-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>62<\/b>, 463\u2013472 (2006).","DOI":"10.1007\/s00228-006-0133-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli WE, Mikus G. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. <i>Clin. Pharmacol. Ther.<\/i>, <b>70<\/b>, 405\u2013414 (2001).","DOI":"10.1067\/mcp.2001.119212"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Inaba T, Jurima M, Mahon WA, Kalow W. <i>In vitro<\/i> inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin <i>p<\/i>-hydroxylase and sparteine monooxygenase. <i>Drug Metab. Dispos.<\/i>, <b>13<\/b>, 443\u2013448 (1985).","DOI":"10.1016\/S0090-9556(25)08231-5"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/10\/40_b17-00118\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:36:23Z","timestamp":1750894583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/10\/40_b17-00118\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00118","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}